Cancer sciences xs47 r261 (code 8461)

Cofunding core facility - NMR Expertise Centre

Design and synthesis of inhibitors of the MEP pathway

Development of alpha-subsituted fosmidomycin analogues as antimalarial DOXP reductoisomerase inhibitors

Development of KRN 7000 analogues with an improvement selectivity profile

Development of methotrexate conjugates for the identification of new intracellular targets via the Maspit technology

Development of methotrextate conjugates for the identification of new intracellular targets via the Maspit technology

DiscoverE

Drug discovery for neglected diseases

Evaluation of a new treatment against "blackhead" disease in turkeys (POULTRY 2)

Expedient purification of bioactive small molecules and/or their PEG conjugates using automated preparative HPLC

Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti-infectives

Identification of adaptive mechanisms leading to reduced antibiotic susceptibility in bacterial biofilms using experimental evolution and machine learning approaches

Identification of optimized Aurora Kinase A PROTACs with suitable PK properties for in vivo proof-of-concept studies (OPTIMAPK).

Modified 7-deazapurine nucleoside analogues for the treatment of human African trypanosomiasis: towards a strong proof-of-concept.

Novel treatment for blackhead disease in turkeys

Optimizing PROTACs for Targeted AURKA Degradation Towards an Orally Bioavailable Lead for Proof-Of-Concept Studies.

Pharmacological feasibility of a drug discovery opportunity for a novel cancer immunotherapy

Phar-NMR: Superconducting Fourier 400 MHz NMR Spectrometer as Indispensable Tool in Pharmaceutical Research

Structure-activity studies around Hamamelitannin a natural fabric with attractive quorum sensing inhibitory activity

Study of the interaction between the dopamine D2-like receptors and the μ opioid receptor

Synthese van suikergemodificeerde a-galactosylveramide-analogen als Th1- polariserende NKT-vel antigenen.

Synthesis and evaluation of new antimalarials tackling a unique biosynthetic pathway for isoprenoid synthesis in P. falciparum.

Synthesis of a-GalCer analogues as tools to elucidate the mechanisms of NKT cell polarization.

Synthesis of sugar-modified alpha-galactosylceramide analogs as Th1-polarizing NKT-cell antigens

Synthesis of Th1-polarizing NKT-cell antigens derived from alpha-galactosyl ceramide

Synthesis of therapeutically useful compounds featuring branched-chain carbohydrate moiety

Synthetic optimization of fosmidomycin (analogues) towards selection of a preclinical candidate that combines promising pharmacodynamic bioacailability properties.

Targeting the degradation of proteins involved in neuroblastoma and autoinflammatory diseases with bivalent ligands.

Targeting the degradation of proteins involved in neuroblastoma with bivalent ligands.

Toxoplasmosis: leveraging active purine nucleoside uptake as new therapeutic strategy.

3D Structural Platform for Chemical Excellence.

Development of a new, miniaturized 18F marking method for proteins and peptides with 18 F-FDG as a building block

Dynamic visualization of TCR-induced NKT cell arrest and anergy induction in vivo

Fighting infectious diseases with combination therapy: targetting sociomicrobiological processes to circumvent antimicrobial resistance

in vivo visualization of NKT cell-mediated anti-tumor activity

Molecular elucidation of polarized cytokine responses induced by structural changes in glycolipid antigenten presented by CD1d.

Penetration of antimicrobial agents into biofilms and use of quorum sensing inhibitors as novel anti-biofilm compounds

Targeting transcription factor addiction in acute leukemia (TaTFAL)

The DOXP pathway as novel target for antibacterial chemotherapy

Uncaging the potential of photopharmacology for the treatment of epilepsy